---
title: "Early-Stage Triple-Negative Breast Cancer Journey Beginning, End, and Everything in Between"
slug: "early-stage-triple-negative-breast-cancer-journey-beginning-end-and-everything-in-between"
date: "2023-10-12"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[ASCO guideline-of-breast cancer]]

# Early-Stage Triple-Negative Breast Cancer Journey Beginning, End, and Everything in Between

- DOI: 10.1200/EDBK_390464 43 (June 19, 2023)

INTRODUCTION
THE ROLE OF NEOADJUVANT THERAPY
NAC REGIMENS: WHERE DO WE STAND?
Intensity and Frequency of Chemotherapy Influence Response
The Function of Platinum-Based Therapies in NAC
Chemoimmunotherapy Is the Standard of Care in Stage II and III TNBC
De-Escalation of Anthracycline-Based Therapies
TAILORING POSTNEOADJUVANT THERAPY IN TNBC
The Use of PARP Inhibitors in Early-Stage TNBC
IDENTIFICATION AND MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS
Endocrinopathies
Thyroid Dysregulation
AI
CHECKPOINT INHIBITOR-ASSOCIATED DIABETES MELLITUS
IMMUNE-RELATED HYPOPHYSITIS
CUTANEOUS IRAES
GI IRAES
Colitis
Gastritis
Hepatitis
Musculoskeletal irAEs
FUTURE DIRECTIONS
Using Biomarkers to Optimize Treatment in Early-Stage TNBC
CONCLUSION
